In ~40% of gliomas, the expression of the MGMT gene is silenced due to epigenetic hypermethylation of CpG islands in its promoter region [12], leading to the loss of MGMT expression and increased sensitivity towards alkylating agents [4, 12]. This evidence concerns the gene MGMT and central nervous system cancer.